Examkin

Question

Difficulty: MediumInfectious Diseases

Match each specific clinical presentation and isolated pathogen of infective endocarditis with its most appropriate targeted antimicrobial regimen according to current clinical guidelines.

  • Native valve infective endocarditis caused by methicillin-susceptible Staphylococcus aureus (MSSA)Intravenous cefazolin or nafcillin monotherapy
  • Prosthetic valve infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA)Intravenous vancomycin, rifampin, and gentamicin
  • Native valve infective endocarditis caused by Enterococcus faecalisIntravenous ampicillin combined with ceftriaxone
  • Native valve infective endocarditis caused by highly penicillin-susceptible Viridans group streptococciIntravenous ceftriaxone or aqueous crystalline penicillin G monotherapy

Answer

MSSA on a native valve is paired with intravenous cefazolin or nafcillin monotherapy; MRSA on a prosthetic valve is paired with intravenous vancomycin, rifampin, and gentamicin; Enterococcus faecalis on a native valve is paired with intravenous ampicillin combined with ceftriaxone; and highly penicillin-susceptible Viridans group streptococci on a native valve is paired with intravenous ceftriaxone or aqueous crystalline penicillin G monotherapy.
Guideline-directed therapy for infective endocarditis relies on both the causative organism and the valve type. Native valve MSSA requires an antistaphylococcal beta-lactam for optimal outcomes. Prosthetic valves infected with MRSA mandate vancomycin combined with rifampin (for biofilm penetration) and gentamicin (for early synergy). Enterococcus faecalis requires synergistic bactericidal therapy, heavily relying on dual beta-lactams (ampicillin and ceftriaxone) to avoid the nephrotoxicity of aminoglycosides. Finally, highly susceptible Viridans group streptococci can be safely treated with simple ceftriaxone or penicillin monotherapy.

Step-by-Step Solution

1
Analyze the valve type for each presentation.
Three scenarios involve native valves, while one involves a prosthetic valve.
Prosthetic valves are prone to biofilm formation, significantly altering the required antibiotic strategy (e.g., the necessity of adding rifampin for staphylococcal infections).
2
Evaluate the pathogen susceptibilities.
Identify MSSA (requires beta-lactams), MRSA (requires vancomycin), Enterococcus (requires synergy), and highly susceptible Viridans streptococci (responsive to monotherapy).
Each organism has a distinct resistance profile and cell-wall characteristic that dictates the optimal pharmacologic approach.
3
Match the targeted regimens to the pathogen and valve profiles.
Assign cefazolin/nafcillin to MSSA, the vancomycin/rifampin/gentamicin combination to prosthetic valve MRSA, ampicillin/ceftriaxone to Enterococcus, and ceftriaxone/penicillin G to Viridans streptococci.
This pairs each clinical scenario with the most efficacious, guideline-directed bactericidal regimen while minimizing unnecessary toxicity.

Key Concept

Targeted antimicrobial therapy for infective endocarditis depends heavily on the specific pathogen's susceptibility profile, the need for synergistic bactericidal activity, and the presence of foreign material (prosthetic valves) which requires biofilm-penetrating agents.
Rate this question

Topics

Infectious Diseases

More questions from this topic